As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion ...

Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...

Sales of the drug, which comprised nearly half of Merck’s sales last year, totaling $29.5 billion, are expected to peak ...

Merck (MRK) delivered annual earnings growth of 19.4%, outpacing its own 5-year average growth rate of 13.4%. Profit margins ...

It's the latest in a string of announcements by pharmaceutical manufacturers to build or expand operations in Virginia.

Some four years into its run as an independent women’s health outfit, Organon is parting ways with its first CEO after an ...

Pharmaceutical giant Merck & Co. is breaking ground on a $3 billion expansion of its longtime Elkton manufacturing campus, a ...

The company will begin its domestic investment by starting construction on a $3 billion pharmaceutical manufacturing site in ...

Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of ...

Merck & Co. is starting construction on a $3 billion pharmaceutical manufacturing facility in Elkton that is expected to ...